Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
PHASE1CompletedINTERVENTIONAL
Enrollment
7
Participants
Timeline
Start Date
July 1, 2015
Primary Completion Date
May 29, 2017
Study Completion Date
May 29, 2017
Conditions
Carcinoma, Renal Cell
Interventions
DRUG
Lenvatinib
DRUG
Everolimus
Trial Locations (3)
Unknown
Eisai Trial Site #1, Chiba
Eisai Trial Site #1, Tokyo
Eisai Trial Site #2, Tokyo
All Listed Sponsors
lead
Eisai Co., Ltd.
INDUSTRY
NCT02454478 - Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | Biotech Hunter | Biotech Hunter